Novo Nordisk Price to Book Ratio 2010-2024 | NVO

Historical price to book ratio values for Novo Nordisk (NVO) over the last 10 years. The current price to book ratio for Novo Nordisk as of November 04, 2024 is 30.94.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Novo Nordisk Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-11-01 111.94 inf
2024-06-30 142.20 0.00
2024-03-31 127.91 0.00
2023-12-31 102.32 $3.43 29.82
2023-09-30 89.95 0.00
2023-06-30 79.65 0.00
2023-03-31 78.33 0.00
2022-12-31 66.10 $2.59 25.50
2022-09-30 48.66 0.00
2022-06-30 54.13 0.00
2022-03-31 53.95 0.00
2021-12-31 53.89 $2.44 22.12
2021-09-30 46.20 0.00
2021-06-30 40.09 0.00
2021-03-31 32.27 0.00
2020-12-31 32.98 $2.06 15.98
2020-09-30 32.79 0.00
2020-06-30 30.68 0.00
2020-03-31 28.20 0.00
2019-12-31 26.75 $1.80 14.87
2019-09-30 23.89 0.00
2019-06-30 23.38 0.00
2019-03-31 23.97 0.00
2018-12-31 21.11 $1.62 13.05
2018-09-30 21.60 0.00
2018-06-30 20.93 0.00
2018-03-31 22.35 0.00
2017-12-31 23.95 $1.55 15.47
2017-09-30 21.49 0.00
2017-06-30 18.94 0.00
2017-03-31 15.14 0.00
2016-12-31 15.53 $1.34 11.56
2016-09-30 18.01 0.00
2016-06-30 23.06 0.00
2016-03-31 23.23 0.00
2015-12-31 24.47 $1.37 17.84
2015-09-30 22.85 0.00
2015-06-30 23.07 0.00
2015-03-31 22.50 0.00
2014-12-31 17.57 $1.39 12.68
2014-09-30 19.77 0.00
2014-06-30 19.17 0.00
2014-03-31 18.95 0.00
2013-12-31 15.05 $1.38 10.92
2013-09-30 13.79 0.00
2013-06-30 12.63 0.00
2013-03-31 13.16 0.00
2012-12-31 13.04 $1.25 10.40
2012-09-30 12.61 0.00
2012-06-30 11.61 0.00
2011-12-31 9.05 0.00
2011-09-30 7.81 0.00
2011-06-30 9.84 0.00
2011-03-31 9.83 0.00
2010-12-31 8.71 0.00
2010-09-30 7.62 0.00
2010-06-30 6.27 0.00
2012-03-31 11.08 0.00
2010-03-31 5.97 0.00
2009-12-31 4.85 0.00
2009-09-30 4.78 0.00
2009-06-30 4.14 0.00
2009-03-31 3.65 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $502.334B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Merck (MRK) United States $258.042B 17.12
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69